Absci (ABSI) FCF Margin (2020 - 2026)
Absci (ABSI) posted FCF Margin of 12249.77% for Q1 2026, down 173.82% sequentially from 4473.69% in Q4 2025, and down 1039531.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Absci (ABSI) FCF Margin (2020 - 2026) Analysis & Trends
Absci has reported FCF Margin for 7 years, with the latest figure at 12249.77% in Q1 2026.
- Quarterly FCF Margin fell 1039531.0% year-over-year to 12249.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5365.2% (down 377004.0% YoY) and the FY2025 annual result came in at 3358.29%, down 175251.0% from the prior year.
- FCF Margin retreated to 12249.77% in Q1 2026 per ABSI's latest filing, from 4473.69% in the prior quarter.
- Over five years, FCF Margin peaked at 569.82% in Q2 2023 and troughed at 12249.77% in Q1 2026.
- A 5-year average of 3651.81% and a median of 2124.45% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin soared 756801 bps in 2023, then tumbled 1039531 bps in 2026.
- Over 5 years, FCF Margin stood at 867.26% in 2022, then slumped by 409 bps to 4414.79% in 2023, then jumped by 41 bps to 2600.9% in 2024, then plunged by 72 bps to 4473.69% in 2025, then sank by 174 bps to 12249.77% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 12249.77%, 4473.69%, and 6876.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -8,668.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,668.24% |
| Mar 31, 2026 | -12,249.77% |
| Dec 31, 2025 | -4,473.69% |
| Sep 30, 2025 | -6,876.46% |
| Jun 30, 2025 | -2,882.97% |
| Mar 31, 2025 | -1,854.45% |
| Dec 31, 2024 | -2,574.89% |
| Sep 30, 2024 | -1,221.63% |
| Jun 30, 2024 | -1,352.76% |
| Mar 31, 2024 | -1,988.75% |
| Dec 31, 2023 | -4,419.82% |
| Sep 30, 2023 | -1,433.87% |
| Jun 30, 2023 | -578.85% |
| Mar 31, 2023 | -1,607.49% |
| Dec 31, 2022 | -1,228.52% |
| Sep 30, 2022 | -1,009.41% |
| Jun 30, 2022 | -2,641.42% |
| Mar 31, 2022 | -3,419.54% |
| Dec 31, 2021 | -1,748.97% |
| Sep 30, 2021 | -1,778.23% |